Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage

Inclusion Criteria: * 1\. Age between 20 and 70 years * 2\. Clinical diagnosis of intracerebral hemorrhage 12 month or more from onset * 3\. Hemorrhagic location of unilateral basal ganglia or thalamus * 4\. Moderate to severe neurological symptoms; mRS 3 or 4, and Brunnstrom stage Ⅲ or IV * 5\. No significant neurological impairment before hemorrhage (Pre-hemorrhagic mRS of 0 or 1) * 6\. Subjects who can give informed consent by its self Exclusion Criteria: * 1\. Severe microbleeds found by T2\* * 2\. Hemorrhagic cavity less than 2 mL * 3\. The hemorrhage is due to arteriovenous malformation, cerebral aneurysm, and Moyamoya disease * 4\. Subject showing obvious communication between the hemorrhagic cavity and lateral ventricle on MRI * 5\. Subject showing severe lower extremity contracture (Maximum knee extension less than -15 degrees, Maximum ankle flexion less than 0 degree) * 6\. Subject's body weight less than 45 kg for male and 40kg for female * 7\. Anaemia (Hg \< 10·0 g/dL) * 8\. Thrombocytopaenia (platelet count \< 100,000/mm3) * 9\. Severe heart disease (ischaemic heart disease, heart failure) * 10\. Uncontrolled hypertension, despite antihypertensive therapy * 11\. Carriers of infectious disease: syphilis, HBV, HCV, HIV-1/HIV-2, HTLV-1, parvovirus B19 * 12\. Pregnant or lactating or expecting to become pregnant during the study * 13\. History of malignancy * 14\. Systemic organ failure ALT ≤ 3·0× upper limit of normal Total bilirubin ≤ 1·5× upper limit of normal Serum creatinine ≤ 1·5× upper limit of normal * 15\. Known serious allergy to any agents used in the study * 16\. Contraindication for magnetic resonance imaging * 17\. Any condition that in the judgement of the investigator would place the patient at undue risk